Raxibacumab for the treatment of inhalational anthrax

New England Journal of Medicine

Volumn 361, Issue 2, 2009, Pages 135-144

  Migone, Thi Sau ^a   Subramanian, G Mani ^a   Zhong, John ^a   Healey, Letha M ^a   Corey, Al ^a   Devalaraja, Matt ^a   Lo, Larry ^a   Ullrich, Stephen ^a   Zimmerman, Janelle ^a   Chen, Andrew ^a   Lewis, Maggie ^a   Meister, Gabriel ^b   Gillum, Karen ^b   Sanford, Daniel ^b   Mott, Jason ^b   Bolmer, Sally D ^a  

^a GLAXOSMITHKLINE   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; MONOCLONAL ANTIBODY; PLACEBO; RAXIBACUMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ARM PAIN; ARTHRALGIA; ARTICLE; BACILLUS ANTHRACIS; BACTEREMIA; CHOLECYSTITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DROWSINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; EXPERIMENTAL MONKEY; EXPERIMENTAL RABBIT; FEMALE; FLU LIKE SYNDROME; HEADACHE; HUMAN; INFECTION PREVENTION; INJECTION SITE PHLEBITIS; LEG PAIN; LEUKOPENIA; LOW BACK PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; NAUSEA; NONHUMAN; PAIN; PHARYNGITIS; PRIORITY JOURNAL; PROTHROMBIN TIME; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RHINITIS; SCHIZOPHRENIA; SIDE EFFECT; SINGLE BLIND PROCEDURE; SURVIVAL RATE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 67650500264     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0810603     Document Type: Article

References (20)

1. Holty JE, Bravata DM, Liu H, Olshen RA, McDonald KM, Owens DK. Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med 2006;144:270-80.
2. Inglesby TV, O'Toole T, Henderson DA, et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 2002;287:2236-52.
3. Abramova FA, Grinberg LM, Yampolskaya OV, Walker DH. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci U S A 1993;90:2291-4.
4. Jernigan DB, Raghunathan PL, Bell BP, et al. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis 2002;8:1019-28.
5. Jernigan JA, Stephens DS, Ashford DA, et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 2001;7:933-44.
6. Ascenzi P, Visca P, Ippolito G, Spallarossa A, Bolognesi M, Montecucco C. Anthrax toxin: a tripartite lethal combination. FEBS Lett 2002;531:384-8.
7. Maynard JA, Maassen CB, Leppla SH, et al. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat Biotechnol 2002;20:597-601.
8. Friedlander AM, Pittman PR, Parker GW. Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax. JAMA 1999;282:2104-6.
9. Walsh JJ, Pesik N, Quinn CP, et al. A case of naturally acquired inhalation anthrax: clinical care and analyses of antiprotective antigen immunoglobulin G and lethal factor. Clin Infect Dis 2007;44:968-71.
10. Fritz DL, Jaax NK, Lawrence WB, et al. Pathology of experimental inhalation anthrax in the rhesus monkey. Lab Invest 1995;73:691-702.
11. Twenhafel NA, Leffel E, Pitt ML. Pathology of inhalational anthrax infection in the African green monkey. Vet Pathol 2007;44:716-21.
12. Vasconcelos D, Barnewall R, Babin M, et al. Pathology of inhalation anthrax in cynomolgus monkeys (Macaca fascicularis). Lab Invest 2003;83:1201-9.
13. Zaucha GM, Pitt LM, Estep J, Ivins BE, Friedlander AM. The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation. Arch Pathol Lab Med 1998;122:982-92.
14. Friedlander AM, Welkos SL, Pitt ML, et al. Postexposure prophylaxis against experimental inhalational anthrax. J Infect Dis 1993;167:1239-42.
15. Kao LM, Bush K, Barnewall R, et al. Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model. Antimicrob Agents Chemother 2006;50:3535-42.
16. Subramanian GM, Cronin PW, Poley G, et al. A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. Clin Infect Dis 2005;41:12-20.
17. Hering D, Thompson W, Hewetson J, Little S, Norris S, Pace-Templeton J. Validation of the anthrax lethal toxin neutralization assay. Biologicals 2004;32:17-27.
18. Cui X, Li Y, Moayeri M, et al. Late treatment with a protective antigen-directed monoclonal antibody improves hemodynamic function and survival in a lethal toxin-infused rat model of anthrax sepsis. J Infect Dis 2005;191:422-34.
19. Russell PK. Project BioShield: what it is, why it is needed, and its accomplishments so far. Clin Infect Dis 2007;45:Suppl 1:S68-S72.
20. Young JA, Collier RJ. Anthrax toxin: receptor binding, internalization, pore formation, and translocation. Annu Rev Biochem 2007;76:243-65.